WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562386

CAS#: 38183-03-8

Description: 7,8-Dihydroxyflavone is an agonist of tyrosine receptor kinase B (TrkB). It acts by promoting immature neuron survival after TBI through activation of the BDNF signaling pathway.

Chemical Structure

CAS# 38183-03-8

Theoretical Analysis

MedKoo Cat#: 562386
Name: 7,8-Dihydroxyflavone
CAS#: 38183-03-8
Chemical Formula: C15H10O4
Exact Mass: 254.0579
Molecular Weight:
Elemental Analysis: Chemical Formula: C15H10O4 Exact Mass: 254.0579 Molecular Weight: 254.2410 Elemental Analysis: C, 70.86; H, 3.96; O, 25.17

Price and Availability

Size Price Availability Quantity
10.0mg USD 180.0 2 Weeks
100.0mg USD 300.0 2 Weeks
250.0mg USD 550.0 2 Weeks
Bulk inquiry

Synonym: 7,8-Dihydroxyflavone; DHF; 7,8-DHF;

IUPAC/Chemical Name: 7,8-Dihydroxy-2-phenyl-chromen-4-one


InChi Code: InChI=1S/C15H10O4/c16-11-7-6-10-12(17)8-13(19-15(10)14(11)18)9-4-2-1-3-5-9/h1-8,16,18H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wurzelmann M, Romeika J, Sun D. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. Neural Regen Res. 2017 Jan;12(1):7-12. doi: 10.4103/1673-5374.198964. Review. PubMed PMID: 28250730; PubMed Central PMCID: PMC5319242.

2: Du X, Hill RA. The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. J Mol Neurosci. 2016 Nov;60(3):336-348. Epub 2016 Aug 15. Review. PubMed PMID: 27525638.

3: Zhang JC, Yao W, Hashimoto K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. Curr Neuropharmacol. 2016;14(7):721-31. Review. PubMed PMID: 26786147; PubMed Central PMCID: PMC5050398.

4: Liu C, Chan CB, Ye K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Transl Neurodegener. 2016 Jan 6;5:2. doi: 10.1186/s40035-015-0048-7. eCollection 2016. Review. PubMed PMID: 26740873; PubMed Central PMCID: PMC4702337.

5: Moosavi F, Hosseini R, Saso L, Firuzi O. Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Devel Ther. 2015 Dec 21;10:23-42. doi: 10.2147/DDDT.S96936. eCollection 2016. Review. PubMed PMID: 26730179; PubMed Central PMCID: PMC4694682.

6: Du X, Hill RA. 7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders. Neurochem Int. 2015 Oct;89:170-80. doi: 10.1016/j.neuint.2015.07.021. Epub 2015 Jul 26. Review. PubMed PMID: 26220903.

7: Ragen BJ, Seidel J, Chollak C, Pietrzak RH, Neumeister A. Investigational drugs under development for the treatment of PTSD. Expert Opin Investig Drugs. 2015 May;24(5):659-72. doi: 10.1517/13543784.2015.1020109. Epub 2015 Mar 14. Review. PubMed PMID: 25773140.

8: Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM. Small molecules activating TrkB receptor for treating a variety of CNS disorders. CNS Neurol Disord Drug Targets. 2013 Nov;12(7):1066-77. Review. PubMed PMID: 23844685.

9: Obianyo O, Ye K. Novel small molecule activators of the Trk family of receptor tyrosine kinases. Biochim Biophys Acta. 2013 Oct;1834(10):2213-8. doi: 10.1016/j.bbapap.2012.08.021. Epub 2012 Sep 6. Review. PubMed PMID: 22982231; PubMed Central PMCID: PMC3602283.

10: Andero R, Ressler KJ. Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav. 2012 Jul;11(5):503-12. doi: 10.1111/j.1601-183X.2012.00801.x. Epub 2012 May 11. Review. PubMed PMID: 22530815; PubMed Central PMCID: PMC3389160.